BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22173604)

  • 1. Resistance to angiogenesis inhibitors in renal cell carcinoma.
    Tamaskar I; Dhillon J; Pili R
    Clin Adv Hematol Oncol; 2011 Feb; 9(2):101-10. PubMed ID: 22173604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.
    Saylor PJ; Escudier B; Michaelson MD
    Clin Genitourin Cancer; 2012 Jun; 10(2):77-83. PubMed ID: 22382009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms.
    Buczek M; Escudier B; Bartnik E; Szczylik C; Czarnecka A
    Biochim Biophys Acta; 2014 Jan; 1845(1):31-41. PubMed ID: 24135488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis.
    Ebbinghaus SW; Gordon MS
    Hematol Oncol Clin North Am; 2004 Oct; 18(5):1143-59, ix-x. PubMed ID: 15474339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Not Available].
    Falkowski S
    Bull Cancer; 2018 Dec; 105 Suppl 3():S255-S260. PubMed ID: 30595154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel antiangiogenic therapies for renal cell cancer.
    Gordon MS
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6377S-81S. PubMed ID: 15448034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Renal cell carcinoma: the end of a tunnel?].
    Ravaud A; Dilhuydy MS
    Pathol Biol (Paris); 2006 May; 54(4):206-8. PubMed ID: 16530346
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.
    Ainsworth NL; Lee JS; Eisen T
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-angiogenic therapy in renal cell cancer.
    Srinivasan R; Armstrong AJ; Dahut W; George DJ
    BJU Int; 2007 May; 99(5 Pt B):1296-300. PubMed ID: 17441927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
    de Bazelaire C; Alsop DC; George D; Pedrosa I; Wang Y; Michaelson MD; Rofsky NM
    Clin Cancer Res; 2008 Sep; 14(17):5548-54. PubMed ID: 18765547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.
    Pircher A; Jöhrer K; Kocher F; Steiner N; Graziadei I; Heidegger I; Pichler R; Leonhartsberger N; Kremser C; Kern J; Untergasser G; Gunsilius E; Hilbe W
    Oncotarget; 2016 Apr; 7(15):20109-23. PubMed ID: 26956051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The pathologist's role in the neoadjuvant strategy of renal-cell carcinoma].
    Leroy X; Edeline J; Rioux-Leclercq N
    Ann Pathol; 2011 Dec; 31(6):466-71. PubMed ID: 22172119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging antiangiogenics for renal cancer.
    Domblides C; Gross-Goupil M; Quivy A; Ravaud A
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):495-511. PubMed ID: 24274612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The possible role of chemotherapy in antiangiogenic drug resistance.
    Bocci G; Loupakis F
    Med Hypotheses; 2012 May; 78(5):646-8. PubMed ID: 22365648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
    van der Mijn JC; Mier JW; Broxterman HJ; Verheul HM
    Drug Resist Updat; 2014; 17(4-6):77-88. PubMed ID: 25457974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of angiogenesis inhibitory combination therapies for treatment of renal cell carcinoma].
    Bartsch G; Eggert K; Soker S; Fiedler W; Laack E; Volkmer BG; Gschwend J; Bokemeyer C; Hautmann R; Schuch G
    Urologe A; 2007 Sep; 46(9):1289-90. PubMed ID: 17624513
    [No Abstract]   [Full Text] [Related]  

  • 17. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
    Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
    BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models.
    Schirner M; Hoffmann J; Menrad A; Schneider MR
    Clin Cancer Res; 1998 May; 4(5):1331-6. PubMed ID: 9607594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interview with professor Per-Anders Abrahamson: angiogenesis and renal cell carcinoma.
    Abrahamson PA
    Eur Urol; 2006 Sep; 50(3):609-11. PubMed ID: 16824676
    [No Abstract]   [Full Text] [Related]  

  • 20. Angiogenesis and angiogenic inhibitors in renal cell carcinoma.
    Sawhney R; Kabbinavar F
    Curr Urol Rep; 2008 Jan; 9(1):26-33. PubMed ID: 18366971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.